In Vivo Efficacy of Recombinant Methioninase Is Enhanced by the Combination of Polyethylene Glycol Conjugation and Pyridoxal 5′-Phosphate Supplementation

Xinghua Sun, Zhijian Yang, Shukuan Li, Yuying Tan, Nan Zhang, Xiaoen Wang, Shigeo Yagi, Takayuki Yoshioka, Akio Takimoto, Kenji Mitsushima, Akinori Suginaka, Eugene P. Frenkel, Robert M. Hoffman

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Recombinant methioninase (rMETase) is an enzyme active in preclinical mouse models of human cancer. The efficacy of rMETase is due to depletion of plasma methionine, an amino acid for which tumors generally have an abnormally high methionine requirement. Furthermore, transient methionine depletion results in a markedly increased sensitivity of the tumors to several chemotherapeutic agents. This study characterized methods to prolong the half-life of rMETase to extend the in vivo period of depletion of plasma and tumor methionine. In the present study, rMETase was coupled to methoxypolyethylene glycol succinimidyl glutarate-5000 in order to prolong the half-life of rMETase and thus extend the in vivo period of depletion of plasma and tumor methionine. Matrix-assisted laser desorption ionization mass spectrometry indicated that one sub-unit of rMETase was modified by approximately 4, 6 and 8 PEG molecules when rMETase was PEGylated at molar ratios of PEG/rMETase of 30/1, 60/1, and 120/1, respectively. PEG-rMETase (120/1) had a serum half-life increase of 20-fold, and methionine depletion time increased 12-fold compared to unmodified rMETase. The increase in in vivo half-life depended on the extent of PEGylation of rMETase. In addition, a remarkable prolongation of in vivo activity and effective methionine depletion by the PEG-rMETase was achieved by the simultaneous administration of pyridoxal 5′-phosphate. PEGylation also reduced the immunogenicity of rMETase. The extent of reduction in immunogenicity depended on the number of residues PEGylated. PEG-rMETase 30/1 had a 10-fold decrease in IgG titer while PEG-rMETase 120/1 had a 104-fold decreased titer compared to naked rMETase. Thus, the molecular modification of PEGylation confers critical new properties to rMETase for development as a cancer therapeutic.

Original languageEnglish (US)
Pages (from-to)8377-8383
Number of pages7
JournalCancer Research
Volume63
Issue number23
StatePublished - Dec 1 2003

Fingerprint

Pyridoxal Phosphate
Methionine
Half-Life
Neoplasms
L-methionine gamma-lyase
Glutarates
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Immunoglobulin G
PEG-methioninase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

In Vivo Efficacy of Recombinant Methioninase Is Enhanced by the Combination of Polyethylene Glycol Conjugation and Pyridoxal 5′-Phosphate Supplementation. / Sun, Xinghua; Yang, Zhijian; Li, Shukuan; Tan, Yuying; Zhang, Nan; Wang, Xiaoen; Yagi, Shigeo; Yoshioka, Takayuki; Takimoto, Akio; Mitsushima, Kenji; Suginaka, Akinori; Frenkel, Eugene P.; Hoffman, Robert M.

In: Cancer Research, Vol. 63, No. 23, 01.12.2003, p. 8377-8383.

Research output: Contribution to journalArticle

Sun, X, Yang, Z, Li, S, Tan, Y, Zhang, N, Wang, X, Yagi, S, Yoshioka, T, Takimoto, A, Mitsushima, K, Suginaka, A, Frenkel, EP & Hoffman, RM 2003, 'In Vivo Efficacy of Recombinant Methioninase Is Enhanced by the Combination of Polyethylene Glycol Conjugation and Pyridoxal 5′-Phosphate Supplementation', Cancer Research, vol. 63, no. 23, pp. 8377-8383.
Sun, Xinghua ; Yang, Zhijian ; Li, Shukuan ; Tan, Yuying ; Zhang, Nan ; Wang, Xiaoen ; Yagi, Shigeo ; Yoshioka, Takayuki ; Takimoto, Akio ; Mitsushima, Kenji ; Suginaka, Akinori ; Frenkel, Eugene P. ; Hoffman, Robert M. / In Vivo Efficacy of Recombinant Methioninase Is Enhanced by the Combination of Polyethylene Glycol Conjugation and Pyridoxal 5′-Phosphate Supplementation. In: Cancer Research. 2003 ; Vol. 63, No. 23. pp. 8377-8383.
@article{fe5b2cc6263941fba157cab471c8dfb5,
title = "In Vivo Efficacy of Recombinant Methioninase Is Enhanced by the Combination of Polyethylene Glycol Conjugation and Pyridoxal 5′-Phosphate Supplementation",
abstract = "Recombinant methioninase (rMETase) is an enzyme active in preclinical mouse models of human cancer. The efficacy of rMETase is due to depletion of plasma methionine, an amino acid for which tumors generally have an abnormally high methionine requirement. Furthermore, transient methionine depletion results in a markedly increased sensitivity of the tumors to several chemotherapeutic agents. This study characterized methods to prolong the half-life of rMETase to extend the in vivo period of depletion of plasma and tumor methionine. In the present study, rMETase was coupled to methoxypolyethylene glycol succinimidyl glutarate-5000 in order to prolong the half-life of rMETase and thus extend the in vivo period of depletion of plasma and tumor methionine. Matrix-assisted laser desorption ionization mass spectrometry indicated that one sub-unit of rMETase was modified by approximately 4, 6 and 8 PEG molecules when rMETase was PEGylated at molar ratios of PEG/rMETase of 30/1, 60/1, and 120/1, respectively. PEG-rMETase (120/1) had a serum half-life increase of 20-fold, and methionine depletion time increased 12-fold compared to unmodified rMETase. The increase in in vivo half-life depended on the extent of PEGylation of rMETase. In addition, a remarkable prolongation of in vivo activity and effective methionine depletion by the PEG-rMETase was achieved by the simultaneous administration of pyridoxal 5′-phosphate. PEGylation also reduced the immunogenicity of rMETase. The extent of reduction in immunogenicity depended on the number of residues PEGylated. PEG-rMETase 30/1 had a 10-fold decrease in IgG titer while PEG-rMETase 120/1 had a 104-fold decreased titer compared to naked rMETase. Thus, the molecular modification of PEGylation confers critical new properties to rMETase for development as a cancer therapeutic.",
author = "Xinghua Sun and Zhijian Yang and Shukuan Li and Yuying Tan and Nan Zhang and Xiaoen Wang and Shigeo Yagi and Takayuki Yoshioka and Akio Takimoto and Kenji Mitsushima and Akinori Suginaka and Frenkel, {Eugene P.} and Hoffman, {Robert M.}",
year = "2003",
month = "12",
day = "1",
language = "English (US)",
volume = "63",
pages = "8377--8383",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - In Vivo Efficacy of Recombinant Methioninase Is Enhanced by the Combination of Polyethylene Glycol Conjugation and Pyridoxal 5′-Phosphate Supplementation

AU - Sun, Xinghua

AU - Yang, Zhijian

AU - Li, Shukuan

AU - Tan, Yuying

AU - Zhang, Nan

AU - Wang, Xiaoen

AU - Yagi, Shigeo

AU - Yoshioka, Takayuki

AU - Takimoto, Akio

AU - Mitsushima, Kenji

AU - Suginaka, Akinori

AU - Frenkel, Eugene P.

AU - Hoffman, Robert M.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Recombinant methioninase (rMETase) is an enzyme active in preclinical mouse models of human cancer. The efficacy of rMETase is due to depletion of plasma methionine, an amino acid for which tumors generally have an abnormally high methionine requirement. Furthermore, transient methionine depletion results in a markedly increased sensitivity of the tumors to several chemotherapeutic agents. This study characterized methods to prolong the half-life of rMETase to extend the in vivo period of depletion of plasma and tumor methionine. In the present study, rMETase was coupled to methoxypolyethylene glycol succinimidyl glutarate-5000 in order to prolong the half-life of rMETase and thus extend the in vivo period of depletion of plasma and tumor methionine. Matrix-assisted laser desorption ionization mass spectrometry indicated that one sub-unit of rMETase was modified by approximately 4, 6 and 8 PEG molecules when rMETase was PEGylated at molar ratios of PEG/rMETase of 30/1, 60/1, and 120/1, respectively. PEG-rMETase (120/1) had a serum half-life increase of 20-fold, and methionine depletion time increased 12-fold compared to unmodified rMETase. The increase in in vivo half-life depended on the extent of PEGylation of rMETase. In addition, a remarkable prolongation of in vivo activity and effective methionine depletion by the PEG-rMETase was achieved by the simultaneous administration of pyridoxal 5′-phosphate. PEGylation also reduced the immunogenicity of rMETase. The extent of reduction in immunogenicity depended on the number of residues PEGylated. PEG-rMETase 30/1 had a 10-fold decrease in IgG titer while PEG-rMETase 120/1 had a 104-fold decreased titer compared to naked rMETase. Thus, the molecular modification of PEGylation confers critical new properties to rMETase for development as a cancer therapeutic.

AB - Recombinant methioninase (rMETase) is an enzyme active in preclinical mouse models of human cancer. The efficacy of rMETase is due to depletion of plasma methionine, an amino acid for which tumors generally have an abnormally high methionine requirement. Furthermore, transient methionine depletion results in a markedly increased sensitivity of the tumors to several chemotherapeutic agents. This study characterized methods to prolong the half-life of rMETase to extend the in vivo period of depletion of plasma and tumor methionine. In the present study, rMETase was coupled to methoxypolyethylene glycol succinimidyl glutarate-5000 in order to prolong the half-life of rMETase and thus extend the in vivo period of depletion of plasma and tumor methionine. Matrix-assisted laser desorption ionization mass spectrometry indicated that one sub-unit of rMETase was modified by approximately 4, 6 and 8 PEG molecules when rMETase was PEGylated at molar ratios of PEG/rMETase of 30/1, 60/1, and 120/1, respectively. PEG-rMETase (120/1) had a serum half-life increase of 20-fold, and methionine depletion time increased 12-fold compared to unmodified rMETase. The increase in in vivo half-life depended on the extent of PEGylation of rMETase. In addition, a remarkable prolongation of in vivo activity and effective methionine depletion by the PEG-rMETase was achieved by the simultaneous administration of pyridoxal 5′-phosphate. PEGylation also reduced the immunogenicity of rMETase. The extent of reduction in immunogenicity depended on the number of residues PEGylated. PEG-rMETase 30/1 had a 10-fold decrease in IgG titer while PEG-rMETase 120/1 had a 104-fold decreased titer compared to naked rMETase. Thus, the molecular modification of PEGylation confers critical new properties to rMETase for development as a cancer therapeutic.

UR - http://www.scopus.com/inward/record.url?scp=10744223928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744223928&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 8377

EP - 8383

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 23

ER -